Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration

Maurizio Parodi, Pierluigi Iacono, Carlo Spina, Lorenzo Iuliano, Giuseppe Giudice, Ugo Introini, Francesco Bandello

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

PURPOSE:: To investigate the effect of intravitreal ranibizumab on extrafoveal choroidal neovascularization secondary to age-related macular degeneration. METHODS:: Eighteen eyes affected by extrafoveal choroidal neovascularization secondary to age-related macular degeneration were prospectively enrolled in this study. After an initial intravitreal ranibizumab, all patients were reevaluated monthly over 12 months of follow-up. Further retreatments were performed on a pro re nata basis, depending on detection of any type of fluid on optical coherence tomography and/or the presence of leakage on fluorescein angiography. Primary outcome measures were mean changes in best-corrected visual acuity and the proportion of eyes gaining at least 15 letters (3 Early Treatment Diabetic Retinopathy Study [ETDRS] lines) at the end of the follow-up. Secondary outcome measures were central macular thickness variations and changes in choroidal neovascularization size. RESULTS:: Mean best-corrected visual acuity presented a significant improvement during the follow-up period, being 0.3 ± 0.2 logMAR at baseline and 0.2 ± 0.2 logMAR at the 12-month examination (P < 0.001). An improvement of at least 3 EDTRS lines was achieved by 6 eyes (33.3%), whereas 6 patients (33.3%) gained 1 to 2 lines. The mean central macular thickness at baseline was 314 ± 87 μm, changing to 268 ± 65 μm at the 12-month examination (P = 0.003). The mean lesion size was 1.4 ± 1.4 mm and remained stable throughout the follow-up, being 1.8 ± 2.9 mm at 12 months (P = 0.64). CONCLUSION:: Intravitreal ranibizumab administered after a pro re nata regimen with monthly evaluation is a beneficial approach for the management of extrafoveal choroidal neovascularization secondary to age-related macular degeneration over 12 months of follow-up. Further studies are warranted to confirm our preliminary results.

Original languageEnglish
Pages (from-to)2167-2170
Number of pages4
JournalRetina
Volume34
Issue number11
DOIs
Publication statusPublished - Nov 12 2014

Fingerprint

Choroidal Neovascularization
Macular Degeneration
Visual Acuity
Outcome Assessment (Health Care)
Retreatment
Fluorescein Angiography
Optical Coherence Tomography
Diabetic Retinopathy
Ranibizumab
Therapeutics

Keywords

  • age-related macular degeneration
  • extrafoveal choroidal neovascularization
  • ranibizumab

ASJC Scopus subject areas

  • Medicine(all)
  • Ophthalmology

Cite this

Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration. / Parodi, Maurizio; Iacono, Pierluigi; Spina, Carlo; Iuliano, Lorenzo; Giudice, Giuseppe; Introini, Ugo; Bandello, Francesco.

In: Retina, Vol. 34, No. 11, 12.11.2014, p. 2167-2170.

Research output: Contribution to journalArticle

Parodi, Maurizio ; Iacono, Pierluigi ; Spina, Carlo ; Iuliano, Lorenzo ; Giudice, Giuseppe ; Introini, Ugo ; Bandello, Francesco. / Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration. In: Retina. 2014 ; Vol. 34, No. 11. pp. 2167-2170.
@article{4e43ca4fb0a9405b977df632b2d2e301,
title = "Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration",
abstract = "PURPOSE:: To investigate the effect of intravitreal ranibizumab on extrafoveal choroidal neovascularization secondary to age-related macular degeneration. METHODS:: Eighteen eyes affected by extrafoveal choroidal neovascularization secondary to age-related macular degeneration were prospectively enrolled in this study. After an initial intravitreal ranibizumab, all patients were reevaluated monthly over 12 months of follow-up. Further retreatments were performed on a pro re nata basis, depending on detection of any type of fluid on optical coherence tomography and/or the presence of leakage on fluorescein angiography. Primary outcome measures were mean changes in best-corrected visual acuity and the proportion of eyes gaining at least 15 letters (3 Early Treatment Diabetic Retinopathy Study [ETDRS] lines) at the end of the follow-up. Secondary outcome measures were central macular thickness variations and changes in choroidal neovascularization size. RESULTS:: Mean best-corrected visual acuity presented a significant improvement during the follow-up period, being 0.3 ± 0.2 logMAR at baseline and 0.2 ± 0.2 logMAR at the 12-month examination (P < 0.001). An improvement of at least 3 EDTRS lines was achieved by 6 eyes (33.3{\%}), whereas 6 patients (33.3{\%}) gained 1 to 2 lines. The mean central macular thickness at baseline was 314 ± 87 μm, changing to 268 ± 65 μm at the 12-month examination (P = 0.003). The mean lesion size was 1.4 ± 1.4 mm and remained stable throughout the follow-up, being 1.8 ± 2.9 mm at 12 months (P = 0.64). CONCLUSION:: Intravitreal ranibizumab administered after a pro re nata regimen with monthly evaluation is a beneficial approach for the management of extrafoveal choroidal neovascularization secondary to age-related macular degeneration over 12 months of follow-up. Further studies are warranted to confirm our preliminary results.",
keywords = "age-related macular degeneration, extrafoveal choroidal neovascularization, ranibizumab",
author = "Maurizio Parodi and Pierluigi Iacono and Carlo Spina and Lorenzo Iuliano and Giuseppe Giudice and Ugo Introini and Francesco Bandello",
year = "2014",
month = "11",
day = "12",
doi = "10.1097/IAE.0000000000000223",
language = "English",
volume = "34",
pages = "2167--2170",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration

AU - Parodi, Maurizio

AU - Iacono, Pierluigi

AU - Spina, Carlo

AU - Iuliano, Lorenzo

AU - Giudice, Giuseppe

AU - Introini, Ugo

AU - Bandello, Francesco

PY - 2014/11/12

Y1 - 2014/11/12

N2 - PURPOSE:: To investigate the effect of intravitreal ranibizumab on extrafoveal choroidal neovascularization secondary to age-related macular degeneration. METHODS:: Eighteen eyes affected by extrafoveal choroidal neovascularization secondary to age-related macular degeneration were prospectively enrolled in this study. After an initial intravitreal ranibizumab, all patients were reevaluated monthly over 12 months of follow-up. Further retreatments were performed on a pro re nata basis, depending on detection of any type of fluid on optical coherence tomography and/or the presence of leakage on fluorescein angiography. Primary outcome measures were mean changes in best-corrected visual acuity and the proportion of eyes gaining at least 15 letters (3 Early Treatment Diabetic Retinopathy Study [ETDRS] lines) at the end of the follow-up. Secondary outcome measures were central macular thickness variations and changes in choroidal neovascularization size. RESULTS:: Mean best-corrected visual acuity presented a significant improvement during the follow-up period, being 0.3 ± 0.2 logMAR at baseline and 0.2 ± 0.2 logMAR at the 12-month examination (P < 0.001). An improvement of at least 3 EDTRS lines was achieved by 6 eyes (33.3%), whereas 6 patients (33.3%) gained 1 to 2 lines. The mean central macular thickness at baseline was 314 ± 87 μm, changing to 268 ± 65 μm at the 12-month examination (P = 0.003). The mean lesion size was 1.4 ± 1.4 mm and remained stable throughout the follow-up, being 1.8 ± 2.9 mm at 12 months (P = 0.64). CONCLUSION:: Intravitreal ranibizumab administered after a pro re nata regimen with monthly evaluation is a beneficial approach for the management of extrafoveal choroidal neovascularization secondary to age-related macular degeneration over 12 months of follow-up. Further studies are warranted to confirm our preliminary results.

AB - PURPOSE:: To investigate the effect of intravitreal ranibizumab on extrafoveal choroidal neovascularization secondary to age-related macular degeneration. METHODS:: Eighteen eyes affected by extrafoveal choroidal neovascularization secondary to age-related macular degeneration were prospectively enrolled in this study. After an initial intravitreal ranibizumab, all patients were reevaluated monthly over 12 months of follow-up. Further retreatments were performed on a pro re nata basis, depending on detection of any type of fluid on optical coherence tomography and/or the presence of leakage on fluorescein angiography. Primary outcome measures were mean changes in best-corrected visual acuity and the proportion of eyes gaining at least 15 letters (3 Early Treatment Diabetic Retinopathy Study [ETDRS] lines) at the end of the follow-up. Secondary outcome measures were central macular thickness variations and changes in choroidal neovascularization size. RESULTS:: Mean best-corrected visual acuity presented a significant improvement during the follow-up period, being 0.3 ± 0.2 logMAR at baseline and 0.2 ± 0.2 logMAR at the 12-month examination (P < 0.001). An improvement of at least 3 EDTRS lines was achieved by 6 eyes (33.3%), whereas 6 patients (33.3%) gained 1 to 2 lines. The mean central macular thickness at baseline was 314 ± 87 μm, changing to 268 ± 65 μm at the 12-month examination (P = 0.003). The mean lesion size was 1.4 ± 1.4 mm and remained stable throughout the follow-up, being 1.8 ± 2.9 mm at 12 months (P = 0.64). CONCLUSION:: Intravitreal ranibizumab administered after a pro re nata regimen with monthly evaluation is a beneficial approach for the management of extrafoveal choroidal neovascularization secondary to age-related macular degeneration over 12 months of follow-up. Further studies are warranted to confirm our preliminary results.

KW - age-related macular degeneration

KW - extrafoveal choroidal neovascularization

KW - ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=84926018683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926018683&partnerID=8YFLogxK

U2 - 10.1097/IAE.0000000000000223

DO - 10.1097/IAE.0000000000000223

M3 - Article

C2 - 24999724

AN - SCOPUS:84926018683

VL - 34

SP - 2167

EP - 2170

JO - Retina

JF - Retina

SN - 0275-004X

IS - 11

ER -